Fedotozine
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H31NO4 |
| Molar mass | 373.486 g/mol |
| 3D model (Jmol) | |
|
|
|
|
Fedotozine (INN; JO 1196 for the (-) tartrate salt) is an opioid drug of the arylacetamide series which acts as a peripherally-specific, selective κ1-opioid receptor agonist with preference for the κ1A subtype.[1][2] It was under investigation for the treatment of gastrointestinal conditions like irritable bowel syndrome and functional dyspepsia and made it to phase III clinical trials,[1][3][4] but ultimately development was discontinued and it was never marketed.
See also[edit]
References[edit]
- ^ a b Delvaux M (January 2001). "Pharmacology and clinical experience with fedotozine". Expert Opinion on Investigational Drugs. 10 (1): 97–110. PMID 11116283. doi:10.1517/13543784.10.1.97.
- ^ axonmedchem entry
- ^ Barber A, Gottschlich R (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs. 6 (10): 1351–68. PMID 15989506. doi:10.1517/13543784.6.10.1351.
- ^ Lembo A (2006). "Peripheral opioids for functional GI disease: a reappraisal". Digestive Diseases (Basel, Switzerland). 24 (1-2): 91–8. PMID 16699267. doi:10.1159/000090312.
